New Drugs of 2013, Part 1
Pharmacists can learn about new drugs approved by the FDA in 2013, including clinical indications, mechanisms of action, interactions, adverse reactions, and dosing guidelines.
Michael A. Mancano, PharmD
Clinical Professor of Pharmacy PracticeChair, Department of Pharmacy PracticeTemple University School of PharmacyClinical Consultant Pennsylvania HospitalDepartment of PharmacyPhiladelphia, Pennsylvania
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose.
Faculty
Michael A. Mancano, PharmD
Pharmacy Times Office of Continuing Professional Education
Planning Staff—David Heckard; Maryjo Dixon, RPh; and Steve Lin, PharmD, RPh
Pharmacy Times
Editorial Staff—Kirk McKay
EDUCATIONAL OBJECTIVES
Upon completing this continuing education program, participants should be able to:
1. Discuss the clinical indications of the new drugs approved by the FDA in 2013.
2. Explain the various mechanisms of action of the drugs discussed within this program.
3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
4. Identify the most common adverse reactions of the new drugs approved in 2013.
5. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: January 12, 2014
Expiration date: January 12, 2016
Estimated time to complete activity: 2 hours
Fee: Free
Click here to view this activity.
